Abiopharma

🔍 Tsuchimoto Kim R (Director)

Company: Monopar Therapeutics (MNPR)

Report Date: 2026-08-26

Detailed Transactions and Holdings:

• Sold 485 shares of Common Stock at $108.83 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 11,001.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 615 shares of Common Stock at $109.56 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,386.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 700 shares of Common Stock at $110.65 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,686.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 1,098 shares of Common Stock at $111.84 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,588.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 602 shares of Common Stock at $112.93 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,986.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 590 shares of Common Stock at $113.84 per share (Direct)
  Date: 2026-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,396.00 | transaction_form_type: 4 | Footnotes: F1, F7

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.